Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The management of multiple sclerosis in children: a European view

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Alcohol consumption in adolescence is associated with a lower risk of multiple sclerosis in a Danish cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Changes in the sex ratio are a good indicator of changes in MS incidence - No

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Autolog stamcellebehandling til patienter med multipel sklerose

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Diagnostic value of oligoclonal bands in children: A Nationwide Population-Based Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Infections seem to be more frequent before onset of pediatric multiple sclerosis: A Danish nationwide nested case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Angelo Ghezzi
  • Brenda Banwell
  • Alexey Boyko
  • Maria Pia Amato
  • Banu Anlar
  • Morten Blinkenberg
  • Maartje Boon
  • Massimo Filippi
  • Sergiusz Jozwiak
  • Immy Ketelslegers
  • Barbara Kornek
  • Ming Lim
  • Eva Lindstrom
  • Congor Nadj
  • Rinze Neuteboom
  • Maria A Rocca
  • Kevin Rostasy
  • Marc Tardieu
  • Evangeline Wassmer
  • Coriene Catsman-Berrevoets
  • Rogier Hintzen
View graph of relations
About 3-5% of all patients with multiple sclerosis experience the onset of their disease under the age of 16. A significant proportion of paediatric multiple sclerosis patients develop significant cognitive disturbances and persistent physical disability. The high relapse rate and the morbidity in the paediatric multiple sclerosis population has triggered the use of disease-modifying therapies that have been shown to reduce relapse rate, disease progression and cognitive decline in adult patients with multiple sclerosis. Hard evidence for the right treatment and its appropriate timing is scarce in paediatric multiple sclerosis. Nevertheless, expertise in this field has grown thanks to recent open-label trials and experience generated in specialized centres. In spring 2009, a first meeting was held in Rotterdam with clinicians from 11 European countries (one from Canada) that are all active in the management of paediatric multiple sclerosis. One of the aims was to generate a common view on the management of paediatric multiple sclerosis patients. The result of this meeting is presented here to help standardize treatment and to support clinicians with less experience in this field.
Original languageEnglish
JournalMultiple sclerosis (Houndmills, Basingstoke, England)
Volume16
Issue number10
Pages (from-to)1258-67
Number of pages10
DOIs
Publication statusPublished - 1 Oct 2010

ID: 32299256